Core Viewpoint - Jefferies Financial Group Inc. and its trade finance arm Point Bonita Capital are under investigation for potential violations of federal securities laws related to their significant exposure to First Brands Group, which recently filed for bankruptcy [1][2][4]. Group 1: Company Overview - Jefferies is an investment banking and capital markets firm, while Point Bonita Capital serves as its trade finance division [2]. - Both firms were closely associated with First Brands Group, an auto parts supplier that collapsed into bankruptcy in September 2025 [2]. Group 2: Financial Exposure - On October 8, 2025, Jefferies disclosed that it and Point Bonita had approximately $715 million in exposure to First Brands' receivables, accounting for about 25% of Point Bonita's trade finance portfolio [3]. - Following this announcement, Jefferies' stock price dropped by $4.66 per share, or approximately 8%, from $59.10 on October 7, 2025, to $54.44 on October 8, 2025 [3]. Group 3: Legal Investigation - Bleichmar Fonti & Auld LLP is investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors regarding their exposure to First Brands [4].

Core Viewpoint - Coty Inc. is under investigation for potential violations of federal securities laws, following a decline in demand for its products and subsequent disappointing financial results [1][2][3]. Group 1: Company Overview - Coty Inc. is one of the largest beauty companies globally, with a diverse portfolio that includes fragrance, color cosmetics, and skin and body care [2]. - Prestige fragrances represent 60% of Coty's revenues, indicating a significant reliance on this segment [2]. Group 2: Financial Performance - On August 20, 2025, Coty reported disappointing financial results for Q4 and FY 2025, citing issues such as retailer inventory buildup and execution weaknesses in the U.S. market [3]. - The company's stock price fell by $1.05 per share, a decline of over 21%, from $4.86 on August 20, 2025, to $3.81 on August 21, 2025, following the announcement of these results [3]. Group 3: Investigation Details - The investigation by Bleichmar Fonti & Auld LLP is focused on potential misrepresentations regarding the demand for Coty's products and the actual inventory levels held by retailers [1][2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Quanex Building Products Corporation during the specified class period of the upcoming lead plaintiff deadline on November 18, 2025 [2][8]. Group 1: Class Action Details - Investors who purchased Quanex securities between December 12, 2024, and September 5, 2025, may be entitled to compensation through a contingency fee arrangement [3][4]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [4][9]. Group 2: Case Allegations - The lawsuit alleges that Quanex made false and misleading statements regarding its tooling and equipment maintenance policies, particularly in its Tyman Mexico facility, which were significantly underinvested [6]. - It is claimed that the conditions of the tooling and equipment had degraded to near catastrophic levels, leading to significant costs and delays in expected benefits from the Tyman integration [6]. - The lawsuit asserts that Quanex had previously identified these issues, and the positive statements made by the defendants about the company's business and prospects were materially misleading [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [5]. - The firm has recovered hundreds of millions of dollars for investors and was ranked No. 1 for securities class action settlements in 2017 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DexCom, Inc. securities between July 26, 2024, and September 17, 2025, about the upcoming lead plaintiff deadline for a class action lawsuit set for December 29, 2025 [1]. Group 1: Class Action Details - Investors who bought DexCom securities during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by December 29, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its performance in this area [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring systems, which compromised their reliability and posed health risks to users [5]. - It is claimed that the company overstated the enhancements and reliability of the G7 devices while downplaying the severity of the issues [5]. - The allegations suggest that these misrepresentations subjected DexCom to increased regulatory scrutiny and potential legal repercussions, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Legal Action - Shareholders who purchased America's Car-Mart, Inc. securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to recover investor losses [2]. - The investigation follows a significant stock price drop of 18.2% on September 4, 2025, after the company reported a first-quarter loss of 69 cents per share, compared to a net loss of 15 cents per share in the previous year [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its performance in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4].

New York, New York--(Newsfile Corp. - November 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Firefly Aerospace Inc. (NASDAQ: FLY) resulting from allegations that Firefly Aerospace may have issued materially misleading business information to the investing public.SO WHAT: If you purchased Firefly Aerospace securities you may be entitled to compensation without payment of any out of pocket fees or cost ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hormel Foods Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation and Class Action - Shareholders who purchased Hormel securities may be entitled to compensation through a contingency fee arrangement, with no out-of-pocket costs [2]. - Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Recent Developments - On October 29, 2025, The Wall Street Journal reported that Hormel cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility, leading to a 9.1% drop in stock price [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Performance - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and being ranked highly for its performance in this area [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of James Hardie Industries plc during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][5]. Group 1: Class Action Details - Investors who bought James Hardie common stock between May 20, 2025, and August 18, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 23, 2025 [3][5]. - The lawsuit alleges that James Hardie misled investors regarding the strength of its North America Fiber Cement segment, claiming demand was strong while distributors were actually destocking inventory [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions for investors [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors may choose to remain absent or select their own counsel [7].

Core Viewpoint - MoonLake Immunotherapeutics faces a securities class action lawsuit following the announcement of disappointing Phase 3 trial results for its product candidate sonelokimab (SLK), leading to a significant drop in share price by approximately 90% [1][2][6] Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on treating skin inflammatory diseases driven by cytokines IL-17A and IL-17F [3][4] Trial Results and Market Reaction - The Phase 3 trials for SLK revealed that only one of the two trials achieved statistical significance, with results showing substantially lower efficacy compared to the competitor's FDA-approved product, BIMZELX [6] - Following the announcement, MoonLake's share price plummeted by $55.75, or about 90%, on September 29, 2025 [2][6] Allegations of Misleading Information - The lawsuit claims that MoonLake misled investors regarding SLK's trial design and efficacy, asserting that the company made false statements about the advantages of SLK's Nanobody structure over traditional monoclonal antibodies [5][6] - Specific allegations include misleading claims about the clinical benefits of SLK compared to BIMZELX, including the assertion that SLK's structure would provide superior clinical efficacy [5] Legal Proceedings - The class action lawsuit is focused on the propriety of MoonLake's statements about SLK's trial design and data, with a class period defined from March 10, 2024, to September 29, 2025 [3][5] - The lead plaintiff deadline for the lawsuit is set for December 15, 2025 [3]